![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 19-Jun-2013[ | E-mail |
Share ] Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
JUPITER, FL, June 19, 2013 Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.
Christoph Rader, a TSRI associate professor, will be principal investigator of the new three-year study. William Roush, a TSRI professor, associate dean of graduate studies and executive director of medicinal chemistry, will be co-principal investigator.
CLL affects approximately 150,000 patients and causes 4,500 deaths per year in the United States alone. While chemotherapy and radiation are used to treat this slow-growing form of leukemia, currently there are no therapeutic options for the disease in which physicians can selectively target the malignant cells yet spare normal cells and tissues.
The scientists plan to use the recently discovered cell surface receptor TOSO, which is overexpressed in leukemia cells, to create a rapid and effective entry point for delivering drugs to these malignant cells while bypassing normal cells as much as possible.
"We want to create carrier-payload combinations to deliver cytotoxic drugs with very specific targeting," Roush said. "Once we have accomplished that, we expect to optimize potency."
In addition, the team plans to use an antibody fragment to add a second target to the treatmentthe receptor tyrosine kinase ROR1, which is expressed exclusively on leukemia cells.
"This dual-targeting strategy will lay the foundation for further preclinical and clinical investigations in the treatment of this form of leukemia," said Rader. "We also think that the novel biological and chemical components that come from this study can be easily exploited to develop combinations for diseases beyond CLL."
The number of the National Institutes of Health grant, which also involves the laboratories of Adrian Wiestner and Terrence Burke at the National Institutes of Health, is 1U01CA174844.
In addition, Rader has been selected to receive a two-year, $250,000 grant from the Lymphoma Research Foundation. That study will use a similar technology for targeting the receptor tyrosine kinase ROR1 in mantle cell lymphoma, a rare and difficult to treat form of non-Hodgkin lymphoma. The new study will begin this September.
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 19-Jun-2013[ | E-mail |
Share ] Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
JUPITER, FL, June 19, 2013 Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.
Christoph Rader, a TSRI associate professor, will be principal investigator of the new three-year study. William Roush, a TSRI professor, associate dean of graduate studies and executive director of medicinal chemistry, will be co-principal investigator.
CLL affects approximately 150,000 patients and causes 4,500 deaths per year in the United States alone. While chemotherapy and radiation are used to treat this slow-growing form of leukemia, currently there are no therapeutic options for the disease in which physicians can selectively target the malignant cells yet spare normal cells and tissues.
The scientists plan to use the recently discovered cell surface receptor TOSO, which is overexpressed in leukemia cells, to create a rapid and effective entry point for delivering drugs to these malignant cells while bypassing normal cells as much as possible.
"We want to create carrier-payload combinations to deliver cytotoxic drugs with very specific targeting," Roush said. "Once we have accomplished that, we expect to optimize potency."
In addition, the team plans to use an antibody fragment to add a second target to the treatmentthe receptor tyrosine kinase ROR1, which is expressed exclusively on leukemia cells.
"This dual-targeting strategy will lay the foundation for further preclinical and clinical investigations in the treatment of this form of leukemia," said Rader. "We also think that the novel biological and chemical components that come from this study can be easily exploited to develop combinations for diseases beyond CLL."
The number of the National Institutes of Health grant, which also involves the laboratories of Adrian Wiestner and Terrence Burke at the National Institutes of Health, is 1U01CA174844.
In addition, Rader has been selected to receive a two-year, $250,000 grant from the Lymphoma Research Foundation. That study will use a similar technology for targeting the receptor tyrosine kinase ROR1 in mantle cell lymphoma, a rare and difficult to treat form of non-Hodgkin lymphoma. The new study will begin this September.
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-06/sri-sa061913.php
brooke burke Alexa Vega Bram Stoker books Paula Broadwell Photos Veterans Day 2012 Nate Silver stock market
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.